FDA accepts Savara’s MOLBREEVI BLA for priority review in autoimmune PAP
Reuters
Yesterday
FDA accepts Savara’s MOLBREEVI BLA for priority review in autoimmune PAP
Savara Inc. said the U.S. Food and Drug Administration has filed for review its Biologics License Application for MOLBREEVI to treat autoimmune pulmonary alveolar proteinosis. The FDA granted Priority Review and set a PDUFA action date of August 22, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260220017435) on February 20, 2026, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.